Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9761871 | 1.00 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2KMT2AKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL9762430 | 1.00 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2KMT2AKDM4EMEN1 | |
| SCHEMBL689749 | 0.98 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2KMT2AKDM4EMEN1 | |
| SCHEMBL2637184 | 0.98 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2KMT2AKDM4EMEN1 | |
| SCHEMBL805212 | 0.98 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2KMT2AKDM4EMEN1 | |
| SCHEMBL18625014 | 0.92 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2KMT2AKDM4EMEN1 | |
| SCHEMBL9867000 | 0.89 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2KMT2AKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL1179782 | 0.87 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL1180055 | 0.87 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL1467735 | 0.87 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021094827-A1 | USE OF BISANTRENE TO TREAT MEASURABLE RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA | RACE ONCOLOGY LTD. (AU) | 2021-05-20 | — | — | WO | claimed |
| US-20220135544-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2022-05-05 | — | — | US | disclosed |
| WO-2021094827-A1 | USE OF BISANTRENE TO TREAT MEASURABLE RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA | RACE ONCOLOGY LTD. (AU) | 2021-05-20 | — | — | WO | disclosed |
| US-20200131153-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2020-04-30 | — | — | US | disclosed |
| EP-3178818-B1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2019-05-22 | — | — | EP | disclosed |
| US-20180127397-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-9850228-B2 | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3178818-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2017-06-14 | — | — | EP | disclosed |
| CN-104725362-B | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | 阿斯特克斯治疗有限公司 | 2017-04-12 | — | — | CN | disclosed |
| EP-2563775-B1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2017-01-04 | — | — | EP | disclosed |
| US-5227381-A | Anticoagulant | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| EP-0307141-B1 | OXAZOLES AND THIAZOLES FOR THE TREATMENT OF SENILE DEMENTIA | MERCK SHARP & DOHME LTD. (GB) | 1993-01-13 | — | — | EP | disclosed |
| US-5102890-A | Anxiolytic agents | RHONE-POULENC SANTE (FR) | 1992-04-07 | — | — | US | disclosed |
| US-5071855-A | Antihistamines, antiallergens | DOMPE FARMACEUTICI SPA (IT) | 1991-12-10 | — | — | US | disclosed |
| EP-0450066-A1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-09 | — | — | EP | disclosed |
| US-4971958-A | CALCIUM METABOLISM | BOEHRINGER MANNHEIM GMBH (DE) | 1990-11-20 | — | — | US | disclosed |
| EP-0397614-A2 | Pharmacologically active piperdinylimidazopyridines | DOMPE' FARMACEUTICI S.p.A. (IT) | 1990-11-14 | — | — | EP | disclosed |
| EP-0307141-A2 | Oxazoles and thiazoles for the treatment of senile dementia | MERCK SHARP & DOHME LTD. (GB) | 1989-03-15 | — | — | EP | disclosed |
| US-4155905-A | 6-Substituted penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1979-05-22 | — | — | US | disclosed |
| US-4077967-A | 6-Substituted penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131153-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | ALDH1A1 3245/4885SMN1; SMN2 4029/4885KMT2A 1312/4885 |
| US-20180127397-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | ALDH1A1 3245/4885SMN1; SMN2 4029/4885KMT2A 1312/4885 |
| US-20220135544-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | ALDH1A1 3245/4885SMN1; SMN2 4029/4885KMT2A 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.